Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment-Reference-Cited by-同舟云学术

Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment

Published:2021-07 Issue:7 Volume:178 Page:660-671
ISSN:0002-953X
Container-title:American Journal of Psychiatry
language:en
Short-container-title:AJP

Author:

Nunes Edward V.¹,Scodes Jennifer M.¹,Pavlicova Martina¹,Lee Joshua D.¹,Novo Patricia¹,Campbell Aimee N.C.¹,Rotrosen John¹

Affiliation:

1. New York State Psychiatric Institute and Columbia University Irving Medical Center, New York (Nunes, Scodes, Campbell); Department of Biostatistics, Columbia University Mailman School of Public Health, New York (Pavlicova); and New York University Grossman School of Medicine, New York (Lee, Novo, Rotrosen).

Publisher

American Psychiatric Association Publishing

Subject

Psychiatry and Mental health

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options;Pharmacology Biochemistry and Behavior;2024-10

2. Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type;Addiction;2024-09-07

3. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial;Journal of Substance Use and Addiction Treatment;2024-09

4. Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients;Addiction;2024-08-05

5. Potential Implications of Multi-Drug Exposure with Synthetic Cannabinoids: A Scoping Review of Human Case Studies;Psychoactives;2024-08-03